For example, clinical trials involving anti-nerve growth factor (anti-NGF) have been halted due to the emergence of abnormal subchondral fractures and rapidly progressive osteoarthropathy.54 Similarly TrkA inhibitors, employed clinically to treat specific cancers, have also been associated with an elevated fracture risk.55 We therefore cannot rule out that inhibition of bone-related nerves may pose a fracture risk or other skeletal complications in some cases. Here, NGF is linked to skeletal system disorder.